THANK YOU FOR SUBSCRIBING
AIRS Medical effectively added in-vitro diagnostics to its technological portfolio, which also includes venipuncture automation, through the acquisition
Fremont, CA: "We believe we can transform the healthcare ecosystem by solving the current dependency on analog machines by replacing them with data-driven medicine," said Hye-seong Lee, CEO of AIRS Medical. He continued, "Through the Series B funding we've secured, we will be taking our innovative diagnostic solutions to the global market."
AIRS Medical launched in October 2018, is a medical AI firm located in Seoul, Korea, that creates novel products and services to improve health experience and institutional efficiency in areas where low productivity restricts therapeutic value.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
AIRS Medical, a healthcare firm established in South Korea and a member of the Born2Global Centre, has announced a 20 million dollars Series B fundraising round. The Series B investment round included new investors Q Capital Partners and Hanwha Life, as well as additional cash from Klim Ventures. They had previously contributed to the startup's Series A funding.
AIRS Medical, launched in October 2018 by alums of Seoul National University, is a firm that employs digitalized, AI-based diagnostic testing and robotics technology to give a better clinical experience for patients and healthcare practitioners.
AIRS Medical has won the 2019 and 2020 fast MRI Challenges, co-hosted by Facebook AI Research (FAIR) and NYU Langone Health, for its deep learning MR image reconstruction technique. Following these victories, the business successfully developed and marketed its SwiftMRTM technology, which it has been employing to assist the larger healthcare community.
SwiftMRTM is AI-powered MRI reconstruction software that improves MR images recorded under a variety of situations, resulting in increased data accuracy and a better patient experience. The software was authorized by the Korean Ministry of Food and Drug Safety (MFDS) and the US Food and Drug Administration (FDA) in 2021.
In March 2022, AIRS Medical acquired artiQ, an AI- and robotics-based startup that shared AIRS Medical's vision of a world without any sickness. Through the acquisition, AIRS Medical successfully added in-vitro diagnostics to its technology portfolio, including venipuncture automation. Moving forward, AIRS Medical aims to use its exceptional technology and clinical expertise to introduce consecutive diagnostic test solutions that innovate the cost structure of the medical industry.
AIRS Medical purchased artiQ, an AI- and robotics-based firm that shared AIRS Medical's mission of a future without disease, in March 2022. Through the acquisition, AIRS Medical effectively added in-vitro diagnostics to its technological portfolio, including venipuncture automation. AIRS Medical intends to employ its excellent technology and clinical knowledge to create sequential diagnostic test solutions that will alter the medical industry's pricing structure.
More in News